loading
Bristol Myers Squibb Co stock is traded at $54.00, with a volume of 30.94M. It is down -2.32% in the last 24 hours and down -5.78% over the past month. Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$55.28
Open:
$55.2
24h Volume:
30.94M
Relative Volume:
2.65
Market Cap:
$110.27B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
15.16
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
-5.10%
1M Performance:
-5.78%
6M Performance:
+1.26%
1Y Performance:
+15.29%
1-Day Range:
Value
$53.44
$55.33
1-Week Range:
Value
$53.44
$57.60
52-Week Range:
Value
$42.52
$62.89

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
Name
Bristol Myers Squibb Co
Name
Phone
(609) 252-4621
Name
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
Employee
32,500
Name
Twitter
@BMSNEWS
Name
Next Earnings Date
2026-07-30
Name
Latest SEC Filings
Name
BMY's Discussions on Twitter

Compare BMY vs LLY, JNJ, ABBV, MRK, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
BMY icon
BMY
Bristol Myers Squibb Co
54.00 110.27B 48.48B 7.27B 11.91B 3.5626
LLY icon
LLY
Lilly Eli Co
1,098.57 979.64B 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
228.39 549.78B 96.36B 21.04B 17.80B 8.6488
ABBV icon
ABBV
Abbvie Inc
216.49 382.49B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
113.87 281.24B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
147.08 280.64B 54.66B 13.58B 16.05B 7.0171

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-25-26 Initiated RBC Capital Mkts Sector Perform
Feb-20-26 Initiated Barclays Overweight
Jan-07-26 Upgrade UBS Neutral → Buy
Dec-15-25 Upgrade BofA Securities Neutral → Buy
Dec-12-25 Upgrade Guggenheim Neutral → Buy
Nov-13-25 Initiated Scotiabank Sector Perform
Aug-05-25 Downgrade Daiwa Securities Outperform → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Neutral
Apr-22-25 Initiated Piper Sandler Overweight
Dec-16-24 Upgrade Jefferies Hold → Buy
Dec-10-24 Resumed BofA Securities Neutral
Nov-15-24 Initiated Wolfe Research Peer Perform
Nov-13-24 Upgrade Daiwa Securities Neutral → Outperform
Nov-12-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-25-24 Downgrade Citigroup Buy → Neutral
Oct-17-24 Initiated Bernstein Mkt Perform
Jul-29-24 Downgrade Barclays Overweight → Equal Weight
Mar-11-24 Downgrade Societe Generale Buy → Hold
Feb-06-24 Downgrade Redburn Atlantic Buy → Neutral
Jan-03-24 Downgrade BofA Securities Buy → Neutral
Nov-15-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Nov-09-23 Initiated Deutsche Bank Hold
Nov-02-23 Downgrade Daiwa Securities Outperform → Neutral
Oct-27-23 Downgrade BMO Capital Markets Outperform → Market Perform
Oct-27-23 Upgrade HSBC Securities Reduce → Hold
Oct-27-23 Downgrade William Blair Outperform → Mkt Perform
Oct-20-23 Resumed UBS Neutral
Jul-14-23 Initiated HSBC Securities Reduce
Jul-10-23 Initiated SVB Securities Market Perform
Jun-28-23 Initiated Daiwa Securities Outperform
Mar-06-23 Initiated Jefferies Hold
Jan-17-23 Initiated Cantor Fitzgerald Overweight
Nov-18-22 Initiated Credit Suisse Neutral
Oct-10-22 Downgrade Guggenheim Buy → Neutral
Sep-14-22 Downgrade Berenberg Buy → Hold
Jun-03-22 Downgrade Raymond James Outperform → Mkt Perform
Apr-06-22 Resumed Morgan Stanley Underweight
Dec-17-21 Initiated Goldman Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Nov-01-21 Downgrade Argus Buy → Hold
Jul-27-21 Resumed Truist Buy
Apr-30-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-13-21 Upgrade Truist Hold → Buy
Nov-16-20 Upgrade Societe Generale Hold → Buy
Nov-10-20 Resumed Bernstein Mkt Perform
Nov-06-20 Downgrade Gabelli & Co Buy → Hold
Oct-19-20 Upgrade Guggenheim Neutral → Buy
Sep-29-20 Initiated Berenberg Buy
Jul-28-20 Initiated Raymond James Outperform
Apr-02-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Jan-06-20 Resumed Citigroup Buy
Dec-13-19 Upgrade Argus Hold → Buy
Nov-22-19 Resumed Morgan Stanley Equal-Weight
Oct-17-19 Resumed BofA/Merrill Buy
Aug-14-19 Upgrade Atlantic Equities Neutral → Overweight
May-28-19 Initiated Goldman Buy
May-20-19 Downgrade Argus Buy → Hold
May-03-19 Upgrade Barclays Equal Weight → Overweight
May-03-19 Resumed JP Morgan Overweight
Jan-15-19 Upgrade Societe Generale Sell → Buy
Oct-22-18 Downgrade Citigroup Buy → Neutral
View All

Bristol Myers Squibb Co Stock (BMY) Latest News

pulisher
Jun 20, 2026

Bristol-Myers Squibb StockLong-term pipeline and business model under review - AD HOC NEWS

Jun 20, 2026
pulisher
Jun 18, 2026

Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook - The Motley Fool

Jun 18, 2026
pulisher
Jun 18, 2026

Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch

Jun 18, 2026
pulisher
Jun 18, 2026

Bristol-Myers Squibb Co (CELG_r) Institutional Confidence - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Bristol-Myers Squibb Co (CELG_r) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

CHEMUNG CANAL TRUST CO's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus

Jun 18, 2026
pulisher
Jun 18, 2026

Bristol-Myers Squibb Co (CELG_r) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 18, 2026
pulisher
Jun 18, 2026

Bristol-Myers Squibb (BMY) Maintains Quarterly Dividend at $0.63 per Share - GuruFocus

Jun 18, 2026
pulisher
Jun 17, 2026

Bristol-Myers Squibb Co (CELG_r) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes - Yahoo Finance

Jun 17, 2026
pulisher
Jun 17, 2026

Measured Wealth Private Client Group, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus

Jun 17, 2026
pulisher
Jun 17, 2026

Bristol-Myers Squibb Co (BMY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Bristol-Myers Squibb Co (BMY) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch

Jun 17, 2026
pulisher
Jun 17, 2026

Bristol Myers Squibb declares $0.63 quarterly dividend By Investing.com - Investing.com Canada

Jun 17, 2026
pulisher
Jun 17, 2026

Bristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager for Saudi Arabia & Gulf Countries - PR Newswire UK

Jun 17, 2026
pulisher
Jun 17, 2026

BREYANZI® CAR T Cell Therapy Monitoring and Activity Updates Approved in Canada - PR Newswire Canada

Jun 17, 2026
pulisher
Jun 17, 2026

Bristol-Myers Squibb Co (BMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Bristol-Myers Squibb Co (BMY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Bristol-Myers Squibb Co (BMY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 17, 2026
pulisher
Jun 17, 2026

Faithward Advisors, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus

Jun 17, 2026
pulisher
Jun 16, 2026

Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio? - Yahoo Finance

Jun 16, 2026
pulisher
Jun 16, 2026

Bristol-Myers Squibb—ad spending, facts and profile - Ad Age

Jun 16, 2026
pulisher
Jun 16, 2026

Psoriasis around the world - Bristol Myers Squibb

Jun 16, 2026
pulisher
Jun 16, 2026

Bristol Myers Squibb (BMY) Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion - simplywall.st

Jun 16, 2026
pulisher
Jun 16, 2026

Chris Boerner, Board Chair and Chief Executive Officer - Bristol Myers Squibb

Jun 16, 2026
pulisher
Jun 16, 2026

Technologies - Bristol Myers Squibb

Jun 16, 2026
pulisher
Jun 16, 2026

Bristol-Myers Squibb Co (CELG_r) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 16, 2026
pulisher
Jun 15, 2026

BMY Faces Headline Risk Amid Medicare Drug Price Negotiation Pro - GuruFocus

Jun 15, 2026
pulisher
Jun 15, 2026

A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb - Yahoo Finance

Jun 15, 2026
pulisher
Jun 15, 2026

Panagora Asset Management Inc. Raises Holdings in Bristol Myers Squibb Company $BMY - MarketBeat

Jun 15, 2026
pulisher
Jun 15, 2026

Bristol-Myers Squibb (BMY) Stock Analysis: Exploring a 10.41% Upside in the Healthcare Giant - DirectorsTalk Interviews

Jun 15, 2026
pulisher
Jun 14, 2026

Bristol-Myers Squibb Stock (US1078421011): Dividend Safety Under the Microscope - AD HOC NEWS

Jun 14, 2026
pulisher
Jun 13, 2026

How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. - The Motley Fool

Jun 13, 2026
pulisher
Jun 13, 2026

PIMCO RAE US Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus

Jun 13, 2026
pulisher
Jun 13, 2026

Large Cap Core Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus

Jun 13, 2026
pulisher
Jun 13, 2026

Bristol Myers Squibb Company $BMY Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat

Jun 13, 2026
pulisher
Jun 12, 2026

Mike Kelly sells shares in Bristol-Myers Squibb and Comcast, buys Southeast Energy Authority bonds - Investing.com Canada

Jun 12, 2026
pulisher
Jun 12, 2026

Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines? - Yahoo Finance

Jun 12, 2026
pulisher
Jun 12, 2026

A Congress Member Sold Up To $65K In Bristol-Myers Squibb Stock: Here's What You Need To Know - Benzinga

Jun 12, 2026
pulisher
Jun 12, 2026

Bristol Myers Squibb Company $BMY Stake Lifted by Xponance LLC - MarketBeat

Jun 12, 2026
pulisher
Jun 12, 2026

ICICI Prudential Asset Management Co Ltd Sells 39,000 Shares of Bristol Myers Squibb Company $BMY - MarketBeat

Jun 12, 2026
pulisher
Jun 12, 2026

Bristol Myers Squibb’s AI Overhaul And Oncology Trials Shape Value Story - Yahoo Finance

Jun 12, 2026
pulisher
Jun 11, 2026

Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today - Yahoo Finance

Jun 11, 2026
pulisher
Jun 11, 2026

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch

Jun 11, 2026
pulisher
Jun 11, 2026

Takeda’s Zasocitinib Beats BMS’s Sotyktu In Moderate-To-Severe Plaque Psoriasis - Citeline News & Insights

Jun 11, 2026
pulisher
Jun 11, 2026

Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial - Reuters

Jun 11, 2026
pulisher
Jun 11, 2026

Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Benzinga

Jun 11, 2026
pulisher
Jun 11, 2026

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest - pharmaphorum

Jun 11, 2026
pulisher
Jun 10, 2026

Loomis Sayles Strategic Income Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus

Jun 10, 2026
pulisher
Jun 09, 2026

Bristol Myers Squibb Links Brazil Lung Cancer Access To Long Term Story - Yahoo Finance

Jun 09, 2026

Bristol Myers Squibb Co Stock (BMY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
PFE PFE
$25.21
price down icon 2.74%
$123.76
price down icon 1.35%
$337.60
price down icon 1.19%
NVO NVO
$43.19
price down icon 0.76%
AZN AZN
$174.93
price down icon 1.66%
NVS NVS
$147.08
price down icon 2.52%
Cap:     |  Volume (24h):